SCHEMBL20638673

SCHEMBL20638673

Cc1cc(F)ccc1Oc1cccc(C(F)(F)F)c1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 2/20 0.46
▸ SCN8A Q9UQD0 1/20 0.46
▸ SCN10A Q9Y5Y9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22208872 0.87 SCN8A (0.46) MRGPRX4SCN8ASCN10A
SCHEMBL20639015 0.86 SCN8A (0.47) MRGPRX4SCN8ASCN10A
SCHEMBL15918554 0.84 MRGPRX4 (0.44) MRGPRX4
SCHEMBL20638641 0.79 SCN8A (0.56) MRGPRX4SCN8ASCN10A
SCHEMBL25374559 0.79 SCN8A (0.44) MRGPRX4SCN8ASCN10A
SCHEMBL30530129 0.78 SCN10A (0.45) SCN8ASCN10A
SCHEMBL22208764 0.78 SCN8A (0.45) SCN8ASCN10A
SCHEMBL19563683 0.78 SCN8A (0.40) SCN8ASCN10A
SCHEMBL24683800 0.78 SCN8A (0.43) MRGPRX4SCN8ASCN10A
SCHEMBL29804384 0.78 SCN8A (0.43) MRGPRX4SCN8ASCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281057-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 — — US disclosed
EP-3651752-B1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2024-11-20 — — EP disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 — — US disclosed
US-11603351-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-03-14 — — US disclosed
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2021-04-01 — — US disclosed
EP-3651752-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2020-05-20 — — EP disclosed
US-10647661-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-05-12 — — US disclosed
CN-111065383-A Carboxamides useful as sodium channel modulators 沃泰克斯药物股份有限公司 2020-04-24 — — CN disclosed
WO-2019014352-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-01-17 — — WO disclosed
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603351-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A MRGPRX4 635/4885SCN8A 19/4885SCN10A 3/4885
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A MRGPRX4 635/4885SCN8A 19/4885SCN10A 3/4885
US-10647661-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A MRGPRX4 635/4885SCN8A 19/4885SCN10A 3/4885
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A MRGPRX4 635/4885SCN8A 19/4885SCN10A 3/4885
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A MRGPRX4 635/4885SCN8A 19/4885SCN10A 3/4885
US-12281057-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A MRGPRX4 635/4885SCN8A 19/4885SCN10A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback